Investment analysts at Chardan Capital began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a report released on Monday, MarketBeat.com reports. The brokerage set a "buy" rating and a $60.00 price target on the stock. Chardan Capital's target price indicates a potential upside of 71.38% from the company's previous close.
MNPR has been the topic of a number of other research reports. Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler reiterated an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $56.50.
Read Our Latest Analysis on Monopar Therapeutics
Monopar Therapeutics Stock Performance
Shares of Monopar Therapeutics stock traded up $3.09 during trading on Monday, reaching $35.01. The company's stock had a trading volume of 24,388 shares, compared to its average volume of 358,088. The business's fifty day moving average price is $36.96 and its 200-day moving average price is $34.60. The firm has a market cap of $214.26 million, a price-to-earnings ratio of -10.06 and a beta of 0.99. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.27. Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.
Insider Transactions at Monopar Therapeutics
In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 20.50% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $45,000. RA Capital Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at $11,247,000. Geode Capital Management LLC increased its stake in shares of Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after buying an additional 24,530 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the fourth quarter worth $23,435,000. Finally, Gerber LLC acquired a new position in shares of Monopar Therapeutics during the first quarter valued at $204,000. Institutional investors and hedge funds own 1.83% of the company's stock.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recommended Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
